Tough on the tumor. Easier on you and your caregivers.

September 29, 2026

Breaking News!

Publication of ROADS Phase 3 Clinical Trial Data in Journal of Clinical Oncology Recommends GammaTile® as a New Standard-of-Care Option for Newly Diagnosed Operable Brain Metastases1

Phase 3 trial results earn Rapid Communication status, underscoring the importance of the ROADS findings in clinical practice, with the trial authors endorsing GammaTile as a new standard-of-care option for newly diagnosed operable brain metastases1
GammaTile demonstrated 98.7% local tumor control by 12 months, compared to 84.6% for standard-of-care, reducing the risk of surgical bed recurrence at 12 months by more than 90% (HR: 0.07, 95% CI: 0.01–0.56; p=0.012)1*
GammaTile is estimated to reduce the combined risk of tumor recurrence or death by more than 50% compared to standard-of-care (HR: 0.48, 95% CI: 0.30-0.76, p=0.002)1
The median overall survival for patients who received GammaTile was longer than that of patients who received standard-of-care: median overall survival was 42.5 months compared to 17.6 months with standard-of-care (HR: 0.59, 95% CI: 0.37-0.96, p=0.032)1
Treatment with GammaTile did not increase the risk of side effects compared to standard-of-care.1

September 2, 2026

Breaking News!

Tile-Based Radiation Therapy: A New Approach to Tumor Control

ROADS Full 230 Patient Analysis

Final results of a randomized, controlled, phase 3 trial comparing resection and postoperative stereotactic radiation vs. resection plus cesium-131 tile-based radiation for treatment of newly diagnosed brain metastases were presented as a late-breaking Abstract at the 2026 ASCO® Annual Meeting on May 30, 2026.

For patients who had surgery to remove a new brain metastasis, tile-based radiation therapy, compared with standard treatment, showed:

**The cancer was less likely to grow back in the treated area
**Patients were less likely to have worrisome changes on their follow-up brain MRIs
**Patients lived longer
**Treatment with tile-based radiation did not increase the chance of side effects

Gamma Tile

A radiation treatment specifically designed for use inside the brain, GammaTile Therapy gives patients new hope in the fight against brain tumors. It can eliminate the need for traditional repeat radiation treatments and associated hospital or clinic visits, so patients can focus on what matters most—healing.

Watch this animation, which was designed for patients and caregivers to show how GammaTile Therapy works.

Rrecruiting Clinical Trials

A Phase 3 Randomized Controlled Trial of Post-Surgical Stereotactic Radiotherapy (SRT) Versus Surgically Targeted Radiation Therapy (STaRT) With GammaTile for Treatment of Newly Diagnosed Metastatic Brain Tumors | NCT04365374

ENROLLING SITES: 9
Emory University Healthcare

Keck Hospital of USC

Mayfield Brain & Spine

The University of Texas MD Anderson Cancer Center

Memorial Sloan Kettering Cancer Center

Piedmont Atlanta Brain Tumor Center

The University of Kansas Health System

University of Minnesota Health

UT Southwestern Medical Center

A Multi-Center Observational Registry Study of GammaTile Surgically Targeted Radiation Therapy (STaRT) in Intracranial Brain Neoplasms | NCT04427384

ENROLLING SITES: 15
Abbott Northwestern Hospital, part of Allina Health

HonorHealth Scottsdale Osborn Medical Center

Indiana University School of Medicine

Miami Cancer Institute | Baptist Health S. Florida

Mount Sinai Health System

Piedmont Atlanta Brain Tumor Center

St. Alphonsus Regional Medical Center

The University of Kansas Health System

University of Minnesota Health
University of North Carolina at Chapel Hill

UT Health San Antonio

UT Southwestern Medical Center | Simmons Cancer Center

ECU Health Medical Center

Westchester Medical Center

Willis-Knighton Health System

A Intracavitary Carrier – Embedded Cs-131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study | NCT04690348

LEAD INSTITUTION

Memorial Sloan Kettering Cancer Center

An assessment of GammaTile as an upfront boost at the time of resection in combination with STUPP protocol for patients with newly diagnosed GBM.| NCT05342883

ENROLLING SITES: 3
University of Minnesota Health

Piedmont Atlanta Brain Tumor Center

ECU Health

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614

EBCI In The News

Patient Stories

Patient Support Services

Patient Resource Center

VOLUNTEER WITH EBCI

Our case for change

corporate partners

quick form links

General Contact

Patient Inquiry

(425) 444-2215
M-F 9:30am - 4:30pm
T-Th 6:00pm - 9:00pm

wecare@endbraincancer.org

16150 NE 85th St. - Suite #201 | Redmond, WA 98052

© 2026 End Brain Cancer / Chris Elliott Fund All rights reserved.Website by WhimSocial